Short report

Oligoclonal “fingerprint” of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon

CHRISTIAN CONFAVEUX,* COLETTE CHAPUIS-CELLIER,† PHILIPPE ARNAUD,‡ OLIVIER ROBERT,* GILBERT AIMARD,* MICHEL DEVIC*  
From the Service de Neurologie Hôpital Neurologique,* Laboratoire de Biochimie B Hôpital Edouard Herriot,† Lyon, France, Department of Basic and Clinical Immunology and Microbiology, Medical University of South Carolina, Charleston, SC, USA.

SUMMARY The IgG pattern in CSF was studied in 11 patients with multiple sclerosis who exhibited an oligoclonal banding upon thin-layer polyacrylamide gel isoelectric focusing followed by silver stain of unconcentrated CSF. Each patient received beta-interferon intrathecally during a 2 month period. No modification was observed over a 6 month period. In addition, the oligoclonal pattern was remarkably unique for each individual representing a typical “fingerprint” which allowed the identification of any single CSF.

The presence of an oligoclonal pattern of Immunoglobulin G (IgG) in the cerebrospinal fluid (CSF) of patients with multiple sclerosis has been recognized since the 1960s, using electrophoretic techniques.1–3 It has been shown to be stable throughout the course of the disease4,5 with some exceptions.6 The introduction of isoelectric focusing (IEF), with its high resolving capacity for the study of oligoclonal IgG bands,7 has increased the diagnostic yield of CSF analysis in multiple sclerosis.8 With this technique, each patient seems to have a unique band pattern of IgG which remains stable throughout the course of the disease.9–11 In this paper, we report our experience of long-term follow up of CSF IgG band pattern by IEF of unconcentrated CSF in 11 patients with multiple sclerosis.

Material and methods

Eleven subjects with definite multiple sclerosis according to MacAlpine’s criteria12 were studied. The course of the disease was progressive as previously defined.13 All eleven patients exhibited an oligoclonal CSF IgG pattern by thin-layer IEF.14 Oligoclonal pattern was defined as bands present in CSF but not in serum, or more intense in CSF than in serum when equal amounts of CSF and serum IgG were used for IEF.

The patients received natural beta-interferon (IFN) (UPSA Laboratories) intrathecally. Six cases received 100,000 U and the five other patients 640,000 U of IFN at weekly intervals for eight weeks. Paired serum and CSF were obtained prior to each injection and one and four months following the last injection. This survey covered a total period of six months. No other immunomodulating agent was given during the study.

Following standard cytological and biochemical assays, paired serum and CSF were stored at −70°C. IEF was performed on thin-layer polyacrylamide gels (Ampholine pH range 3.5-10) and followed by silver stain using unconcentrated CSF and diluted serum as previously described.14 The total amount of IgG applied to the cathodic side of the gel was 2 μg in each case.

Results

The number, mobility and intensity of the oligoclonal bands of CSF IgG were clearly different from patient to patient (fig a) and showed no qualitative change during the survey within each individual (fig b). From
Oligoclonal "fingerprints" of CSF IgG in multiple sclerosis patients

(a)
(b) a quantitative point of view, no significant change was observed during the survey, considering either the all patients group (table) or the two treatment subgroups separately (data not shown). The moderate increase in CSF IgG levels was due only to case No 7 with a 392% increase from week 1 to week 8. Otherwise, there was no modification in the clinical course of the disease in the 11 patients.

**Discussion**

These results were obtained with IEF of unconcentrated serum and CSF. Overall, the IEF pattern is relatively stable over the six-month period. A new band might present (Fig a). IEF on thin-layer polyacrylamide gels (pH range 3.5–10) followed by silver stain of diluted serum (S) and unconcentrated CSF (C). Multiple sclerosis patients (cases no 1 to 11) received 100,000 U (cases no 1 to 6) or 640,000 U (cases no 7 to 11) of beta-interferon. For each multiple sclerosis individual, paired serum (S) and CSF (C) were run in parallel, after the application (open arrow) of 2 microg. of IgG to the cathodic side (—) of the gel. The small black arrows underline the oligoclonal pattern of CSF IgG, which is clearly different from one patient to another. (b) IEF and silver stain of unconcentrated CSF obtained from the same individual (case No 2). The successive samples were collected during a six-month period as described in the Material and Methods section (3rd week sample is lacking). Note the striking stability of the oligoclonal pattern.

**Table 1**

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>12</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin*</td>
<td>38.5</td>
<td>38.3</td>
<td>39.2</td>
<td>40.3</td>
<td>36.5</td>
<td>38.2</td>
<td>39.2</td>
<td>38.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG*</td>
<td>11.1</td>
<td>11.7</td>
<td>11.4</td>
<td>11.2</td>
<td>10.8</td>
<td>11.4</td>
<td>11.5</td>
<td>11.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin†</td>
<td>345</td>
<td>261</td>
<td>301</td>
<td>342</td>
<td>345</td>
<td>353</td>
<td>365</td>
<td>406</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG†</td>
<td>60.5</td>
<td>60.5</td>
<td>60.9</td>
<td>65.5</td>
<td>65.8</td>
<td>78.1</td>
<td>94.0</td>
<td>90.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG/TP†</td>
<td>11.2</td>
<td>12.8</td>
<td>12.0</td>
<td>11.8</td>
<td>11.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*µg/l. 1 mg/l.
†IgG to total proteins ratio (%).
Oligoclonal "fingerprints" of CSF IgG in multiple sclerosis patients

centrated CSF, a matter of importance as preliminary concentration of CSF is known possibly to result in artefactual patterns.\(^8\) The IgG specificity of the bands was inferred from previous work.\(^14\)

The stability in the band pattern of CSF IgG we observed was not surprising. Indeed, the half-life of beta IFN, administrated in the cerebrospinal space is about 1 hour\(^15\) and each sample was collected one week following each injection. Otherwise, this clonal stability has been documented using concentrated CSF by electrophoresis \(^4\) \(^5\) \(^11\) \(^16\) \(^17\) \(^18\) and by IEF.\(^9\) \(^10\) \(^16\) \(^17\) \(^18\) In fact, some variation in the oligoclonal pattern has been noted.\(^10\) Intensity of bands may vary.\(^4\) \(^11\) Individual bands may appear or disappear\(^6\) with a tendency towards a modest increase in band number with increasing duration of the disease.\(^19\) Moreover, the oligoclonal pattern may be lacking at the initial presentation of the disease and develop later\(^20\) or even never appear in necropsy-proven cases.\(^21\) However, once established, the overall pattern of oligoclonal CSF IgG does not change during the course of the disease in any individual patient. If changes occur, they are confined to individual bands. This stability is not consistently altered by treatment, either corticosteroids,\(^11\) \(^16\) \(^22\) combination of antilymphocyte globulin, azathioprine and prednisone,\(^9\) or natural alpha-IFN.\(^23\) \(^24\) In our experience, the band pattern of CSF IgG was remarkably stable within any individual over a six month period with intrathecal administration of natural beta-IFN.

Another striking finding of this study was the difference of the band pattern from one individual to another. This has been documented previously on concentrated CSF by electrophoresis\(^11\) and IEF.\(^11\) \(^17\) \(^19\)

In summary, each patient had a unique band pattern of CSF IgG which did not change throughout a six month period with administration of natural beta-IFN. This allowed the identification of each individual on the basis of the IEF separation of its CSF IgG, representing indeed a true "fingerprint". Although the exact mechanisms of the production of oligoclonal IgG in the CSF of multiple sclerosis patients is still unclear, it is important to stress that these patterns appeared absolutely fixed during the period of survey of our cases. Therefore, a modification of this oligoclonal pattern could be of significance with regard to the course of multiple sclerosis in individual patients. In addition, the consistency of this pattern could support the theory that oligoclonal CSF IgG have a definite, although yet unknown, antigenic target in multiple sclerosis.

We are indebted to Dr Marion Bernardet, UPSA Laboratories for the provision of natural beta-IFN, Miss Dominique Morel for excellent technical assistance, Mrs S Drogue and M Verger for secretarial work.

This study was supported in part by the Association pour la Recherche sur la Sclérose En Plaques (ARSEP).

References


